بدائل البحث:
significant based » significant cause (توسيع البحث), significant barrier (توسيع البحث), significant burden (توسيع البحث)
significant bias » significant gap (توسيع البحث), significant degs (توسيع البحث), significant i (توسيع البحث)
bias decrease » sizes decrease (توسيع البحث), bias increases (توسيع البحث), a decrease (توسيع البحث)
based case » base case (توسيع البحث), based cancer (توسيع البحث)
significant based » significant cause (توسيع البحث), significant barrier (توسيع البحث), significant burden (توسيع البحث)
significant bias » significant gap (توسيع البحث), significant degs (توسيع البحث), significant i (توسيع البحث)
bias decrease » sizes decrease (توسيع البحث), bias increases (توسيع البحث), a decrease (توسيع البحث)
based case » base case (توسيع البحث), based cancer (توسيع البحث)
-
81
Effect sizes of response bias (unstandardized <i>r</i>) for included studies.
منشور في 2022الموضوعات: -
82
-
83
-
84
The base case analysis.
منشور في 2025"…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …"
-
85
-
86
Base-case results.
منشور في 2025"…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …"
-
87
-
88
Base-case results.
منشور في 2024"…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …"
-
89
Base-case analysis.
منشور في 2023"…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …"
-
90
-
91
-
92
-
93
-
94
-
95
-
96
Risk of bias.
منشور في 2025"…Normally presenting with symptoms such as dyspnea, decreased exercise tolerance, decreased maximal heart rate, and decreased arterial oxygen saturation. …"
-
97
-
98
-
99
-
100